Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Summary of Significant Accounting Policies [Abstract]

Schedule of Significant Expense Categories of Reporting Segment


			Year Ended December 31,
			2025		2024		2023
Revenue			$	176,034	$	125,808	$	87,174
Less⁽¹⁾:
	Cost of revenue			40,837		31,359		29,123
	Research and development expenses
		Research and development		38,673		25,983		22,330
		Regulatory and clinical		26,245		17,534		13,524
	Selling, general and administrative expenses
		Sales		75,709		66,895		53,374
		Marketing		19,146		14,470		9,949
		General and administrative		39,490		30,789		31,788
	Loss from operations			(64,066)		(61,222)		(72,914)
		Other income (expense), net⁽²⁾		(52,801)		(35,151)		(22,194)
		(Provision for) benefit from income taxes		76		(53)		(547)
	Segment net loss		$	(116,791)	$	(96,426)	$	(95,655)

(1) The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.

(2)Other income (expense), net represents the consolidated amounts for interest income, interest expense, change in fair value of convertible note, change in fair value of common stock warrant liability, change in fair value of derivative liability, loss on extinguishment of debt and other income (expense), net as shown on the consolidated statements of operations and comprehensive loss.

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash


	December 31,
	2025		2024		2023
Cash and cash equivalents	$	44,776	$	51,367	$	122,767
Restricted cash		4,709		4,475		4,467
Total cash, cash equivalents and restricted cash	$	49,485	$	55,842	$	127,234